Diabetes Therapy to Improve BMI and Lung Function in CF

Completed · Phase 3

Conditions studied: Cystic Fibrosis, Diabetes Mellitus

In brief

To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF).

Key facts

Study ID

NCT00072904

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

108

Starts

2001-06-01

Expected to finish

2007-12-01

Last updated by the study team

2012-02-28

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• Stanford University — Palo Alto, California, United States
• Baystate Medical Center — Springfield, Massachusetts, United States
• University of Minnesota Medical Center — Minneapolis, Minnesota, United States
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• University of Utah — Salt Lake City, Utah, United States
• St. Michael's Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.